Neuralink
Last reviewed
Apr 30, 2026
Sources
22 citations
Review status
Source-backed
Revision
v1 · 3,311 words
Improve this article
Add missing citations, update stale details, or suggest a clearer explanation.
Suggest edit
CtrlK
Last reviewed
Apr 30, 2026
Sources
22 citations
Review status
Source-backed
Revision
v1 · 3,311 words
Add missing citations, update stale details, or suggest a clearer explanation.
Neuralink Corp. is an American neurotechnology company developing high-bandwidth, fully implantable brain-computer interfaces (BCIs). Co-founded in 2016 by [[elon_musk|Elon Musk]] and a team of seven scientists and engineers, the company is headquartered in Fremont, California, with major facilities in Austin, Texas. Its near-term goal is to restore communication and motor function for people with paralysis, blindness, or other neurological conditions; Musk's longer-term framing for the project has emphasised "human-AI symbiosis" through high-channel-count direct neural communication between brains and computers.
Neuralink's signature product is the N1 Implant (also called "the Link"), a coin-sized device that records and stimulates neural activity through 1,024 electrodes distributed across 64 ultra-thin polymer threads. The threads are inserted into the cortex by a custom surgical robot known as R1, which targets motor cortex tissue while avoiding visible blood vessels. The first human implant occurred on January 28, 2024, in Noland Arbaugh, a 29-year-old quadriplegic patient enrolled in the company's PRIME Study. By early 2025 Neuralink had publicly disclosed at least three implanted human participants, and trials were active or planned in the United States, Canada, the United Kingdom, and the United Arab Emirates.
Neuralink was incorporated in California in mid-2016 and first reported publicly by The Wall Street Journal in March 2017. Elon Musk co-founded the company with eight scientists and engineers from academic neuroscience and from industry: Max Hodak, Vanessa Tolosa, Paul Merolla, Tim Hanson, Benjamin Rapoport, Dongjin (DJ) Seo, Philip Sabes, and Timothy Gardner. Musk has stated publicly that Neuralink was conceived in part as a hedge against the long-term risks he associates with advanced artificial intelligence, with high-bandwidth BCIs serving as a means of keeping humans "in the loop" with future machine intelligence.
Most of the original founding scientists have since left the company. Hodak, who served as president, departed in 2021 and later founded a competitor, Science Corp. Rapoport went on to co-found Precision Neuroscience, another BCI competitor. Sabes, Hanson, and Tolosa also left the company in the early years. By 2024, DJ Seo had been promoted to president, while Musk remained the principal owner and public face of the firm. Day-to-day company affairs have at various times been overseen by Jared Birchall, who manages Musk's family office.
Neuralink was founded in San Francisco and later moved its primary engineering operations to Fremont, California. Following the broader Musk-organisation pivot to Texas, the company began an expansion into the Austin metropolitan area, including a planned three-story, roughly 112,000-square-foot facility in Del Valle, near Tesla's Gigafactory Texas. Headcount, which industry profiles put at around 300 in 2022, has grown alongside trial expansion; reporting on Neuralink's tender offers in 2024 placed the figure in the several hundreds.
Neuralink has raised capital primarily through private rounds led by Founders Fund, the firm co-founded by Peter Thiel, alongside other deep-tech investors. The table below summarises publicly disclosed rounds.
| Year | Round | Amount | Reported valuation | Lead investor(s) |
|---|---|---|---|---|
| 2017 | Series A | ~$27 million | Not disclosed | Founders Fund |
| 2019 | Series B | ~$51 million | Not disclosed | Mixed |
| 2021 | Series C | $205 million | ~$2 billion | Vy Capital, Google Ventures, Founders Fund, DFJ |
| 2023 | Series D | $280 million (extended ~$323 million) | ~$5 billion post-money | Founders Fund |
| 2024 | Tender offer | ~$650 million in secondary sales | ~$8 to $9 billion | Reuters reporting |
| 2025 | Series E | $650 million | ~$9 billion | ARK Invest, Sequoia Capital, Founders Fund |
The 2024 tender offer, first reported by Reuters, allowed existing shareholders to sell stock to new investors at roughly triple the 2023 valuation. The June 2025 Series E added participation from Thrive Capital, QIA, G42, Lightspeed, Valor Equity Partners, Vy Capital, DFJ Growth, and Human Capital. Total disclosed funding through 2025 exceeded $1.3 billion.
The current generation of Neuralink's implant is a hermetically sealed, coin-shaped device about 23 mm in diameter and 8 mm thick that sits flush within the skull, replacing a small disc of bone. It contains a custom application-specific integrated circuit, a rechargeable battery, and a Bluetooth radio for wireless communication with an external receiver such as a laptop or phone. The implant records neural activity through 1,024 microelectrodes arranged on 64 polymer threads. Each thread is roughly four to six micrometres wide, several times thinner than a human hair, and is fabricated from polyimide with thin gold or platinum conductors and iridium oxide electrode sites.
Neuralink's 2019 technical paper, An Integrated Brain-Machine Interface Platform With Thousands of Channels, published as a preprint and in the Journal of Medical Internet Research, described an earlier benchtop platform with 3,072 electrodes across 96 threads. That early system relied on a wired USB-C connection to an external pod sitting behind the ear. The clinical N1 device reduces the channel count to 1,024 in exchange for a fully sealed, wireless, ambulatory package and a smaller, less obtrusive surgical footprint.
The implant runs on a rechargeable battery that the company says supports a typical day of use between charges, with charging by induction through a small headset worn over the skull. The N1 received FDA Breakthrough Device designations for both motor-restoration and speech-restoration use cases.
Threads cannot be inserted by a human surgeon at the precision required, so Neuralink built a custom robot, R1, to carry out the implantation. The system sits on a granite base of about one tonne to suppress vibration and uses a multi-axis arm tipped with a microsurgical needle whose point is roughly 10 to 12 micrometres wide. A vision system combining stereoscopic cameras with optical coherence tomography registers the cortical surface to pre-operative MRI and CT scans and identifies surface vessels to avoid.
For each thread the robot picks up a small polyimide loop, hooks it on the needle's notched "shark-tooth" tip, and inserts the thread three to four millimetres into the motor cortex before retracting and releasing it. Neuralink has stated that R1 can place threads at a rate of about six per minute, completing a 64-thread implantation in roughly 15 to 30 minutes of insertion time. The procedure is supervised by a neurosurgeon who can intervene at any point.
Neuralink has used a small number of high-profile livestreams to introduce its technology and recruit talent. The table below lists the major events.
| Date | Event | Subject(s) | Significance |
|---|---|---|---|
| July 16, 2019 | First public unveiling, San Francisco | Rats, lab rigs | Introduction of polymer-thread platform and surgical robot prototype |
| August 28, 2020 | "Three Little Pigs" livestream | Gertrude and other pigs | Coin-sized v0.9 Link implanted; live cortical signal display |
| April 8, 2021 | "Monkey MindPong" video | Pager, a 9-year-old macaque | Pager played the arcade game Pong with thought alone via two implants |
| November 30, 2022 | Show & Tell event, Fremont | Monkey "Sake" and others | Wireless rechargeable Link demoed; "telepathic typing" video; FDA timeline updates |
| March 20, 2024 | First human livestream | Noland Arbaugh | First public footage of an N1 user playing chess and Civilization VI by mind |
In the 2020 demonstration, Gertrude was one of three pigs used to show that the implant could record from the snout-controlling region of the somatosensory cortex, and that an implant could also be safely removed (a third pig had previously had its device explanted). In 2021 Pager played Pong via two implants in motor cortex, with neural activity initially decoded against joystick movements and then used to control the paddle directly once the joystick was disconnected.
In early 2022, the U.S. Food and Drug Administration declined Neuralink's first investigational device exemption (IDE) application. According to Reuters reporting, the agency's concerns included the implant's lithium battery, the risk that the thin threads might migrate within the brain, and the question of whether the device could be safely explanted without damaging tissue. Neuralink resubmitted, and on May 25, 2023, the company announced that the FDA had granted IDE approval for the PRIME Study (Precise Robotically Implanted Brain-Computer Interface), an early-feasibility trial in patients with quadriplegia from cervical spinal cord injury or amyotrophic lateral sclerosis. The primary endpoint is safety, with secondary endpoints around device function and BCI performance.
The first PRIME implantation took place on January 28, 2024, at the Barrow Neurological Institute in Phoenix, Arizona. The patient, Noland Arbaugh, was 29 at the time and had been paralysed below the shoulders since a 2016 diving accident. Within weeks Arbaugh was using the implant to control a cursor, play online chess, and play Civilization VI; Neuralink reported a peak performance of around 4.6 bits per second on the standard cursor benchmark, later improving to roughly 8 bits per second through algorithmic refinements.
In February and March 2024, a portion of the implant's threads retracted from Arbaugh's cortex, reducing the number of usable electrodes. Neuralink disclosed the issue in a blog post on May 8, 2024, after The Wall Street Journal asked questions about it. The company said that air trapped within the skull after surgery ("pneumocephalus") was a likely contributing factor, and that it had compensated for the loss by improving its decoding pipeline. Public reporting indicated that only about 15% of the originally implanted threads remained well-positioned at one point.
A second human implant, in a patient publicly known as Alex, took place in early August 2024, again at Barrow. Neuralink reported that the procedure used a modified protocol designed to reduce skull-cavity air and place the device closer to the cortical surface, and that no significant thread retraction had occurred. Alex used the device to play video games and to design 3D objects in CAD software. On January 8, 2025, Musk stated in an online conversation that a third patient had been implanted and that all three were performing well.
Neuralink also launched the CONVOY Study in late 2024 to extend N1 control to an investigational assistive robotic arm, allowing existing PRIME participants to attempt physical tasks such as picking up objects or drinking from a cup. Trials have since expanded internationally, including the CAN-PRIME arm in Canada, a UK site at University College London, and a sister trial in the United Arab Emirates.
In parallel with motor BCI work, Neuralink secured a Breakthrough Device designation from the FDA in September 2024 for Blindsight, a planned cortical visual prosthesis intended to restore a low-resolution form of vision in blind patients with intact visual cortex. Blindsight is to write to the brain by stimulating arrays of electrodes in the occipital cortex, in contrast to the N1's primary read-only role. Initial vision quality is expected to resemble early video-game graphics.
Neuralink's public roadmap, as articulated by Musk and the company's engineering leadership in livestreams and in the PRIME Study Brochure, prioritises three near-term goals: restoring digital autonomy (cursor, keyboard, and assistive-device control) for paralysed users; restoring physical autonomy by pairing the N1 with prosthetic and assistive robotic systems; and restoring vision via Blindsight. Beyond these, the company has discussed potential applications for therapies that resemble deep-brain stimulation in conditions such as treatment-resistant depression and obsessive-compulsive disorder, and for restoring speech in patients with severe communication impairment. Musk has also publicly speculated about cognitive augmentation in healthy users as a long-term aspiration, although the company has filed no clinical applications for non-medical use and most BCI researchers regard such uses as remote.
Neuralink is the most publicly visible BCI company, but it operates in a competitive field that includes academic-spinout firms and several venture-backed startups. The table below summarises the leading high-bandwidth BCI players as of 2025; figures should be read as approximate and disclosure-dependent.
| Company | Founded | Headquarters | Approach | Trial stage | Channel count | Notes |
|---|---|---|---|---|---|---|
| [[elon_musk | Neuralink]] | 2016 | Fremont, CA / Austin, TX | Penetrating polymer threads, robot-implanted | Multi-site IDE feasibility (PRIME, CONVOY) | 1,024 electrodes |
| Synchron | 2016 (US-incorporated 2018) | Brooklyn, NY / Melbourne | Endovascular Stentrode, no craniotomy | FDA IDE since 2021; pivotal trial planned | 16 electrodes | First U.S. human implant 2022 |
| Blackrock Neurotech | 2008 | Salt Lake City, UT | Penetrating Utah Array | Multiple academic and IDE trials | 96 to 256 electrodes per array | Utah Array used in BrainGate consortium since 2004 |
| Paradromics | 2015 | Austin, TX | High-density penetrating microwires (Connexus) | First human implant 2025 | ~421 electrodes per module | Modular wireless system |
| Precision Neuroscience | 2021 | New York, NY | Surface microelectrode array (Layer 7) | FDA-cleared for limited intraoperative use 2025 | Up to 4,096 surface electrodes | Co-founded by ex-Neuralink Ben Rapoport |
| Onward Medical | 2014 | Eindhoven, Netherlands | Spinal-cord stimulation, sometimes paired with cortical BCI | Feasibility and pivotal trials | N/A | Restoring movement in SCI |
| BrainGate (consortium) | 2002 | Multi-site academic | Utah Array with offline decoding | Long-running IDE | 96 electrodes | Foundational human BCI work |
| NeuroXess | 2021 | Shanghai, China | Flexible polymer threads | Pre-clinical and early human | Disclosed 256+ channels | Chinese counterpart to Neuralink |
Neuralink's distinguishing claims relative to this peer group are channel count, full implantability with wireless power and data, and the use of a custom surgical robot. Synchron and Precision target less invasive surgery at the cost of lower channel counts and lower spatial resolution. Blackrock and BrainGate have far more cumulative human implant-years but use older arrays with limited bandwidth. Paradromics has aimed for the highest raw channel density, while Onward focuses on stimulation rather than recording.
Neuralink's animal-research practices have been a recurring focus of journalism and advocacy attention. In December 2022, Reuters reported that the U.S. Department of Agriculture's Office of Inspector General had opened an investigation into possible Animal Welfare Act violations at the company, prompted by a federal prosecutor's request and by complaints from current and former employees who said pressure to accelerate timelines had led to rushed surgeries and avoidable animal deaths. Reuters counted at least 1,500 animals used since 2018, including more than 280 sheep, pigs, and monkeys. The Physicians Committee for Responsible Medicine (PCRM) filed multiple complaints citing necropsy records of monkeys obtained from a primate facility at the University of California, Davis, where Neuralink ran some early experiments before bringing animal work in-house. Neuralink has disputed characterisations of avoidable suffering, stating that experimental euthanasias were either pre-planned terminal procedures or driven by complications that informed protocol changes, and that the company has continued to pass USDA inspections.
In 2024, lawyers acting on behalf of Musk and Neuralink reported that the U.S. Securities and Exchange Commission had reopened a probe into the company. PCRM and several members of Congress had previously asked the SEC to consider whether public statements about animal-testing safety could mislead investors. The status and scope of the SEC matter have not been fully publicly resolved.
The partial thread retraction in Noland Arbaugh's implant prompted criticism on two grounds. Engineers and clinicians questioned why the design did not better account for post-surgical brain motion and pneumocephalus, and observers noted that Neuralink delayed public disclosure for several months until The Wall Street Journal asked about the issue. The company's engineering response, including a modified surgical protocol used for the second patient and improvements in decoding to compensate for lost channels, has been more widely accepted than the disclosure handling.
Most of Neuralink's original co-founders had left within five years of the company's founding. Some former employees and academic neuroscientists have suggested that Neuralink's combination of high public expectations and rapid timelines does not always sit well with the slower cadence of clinical neuroscience. Several BCI researchers have observed in interviews that Neuralink's contributions to date are primarily engineering improvements (channel count, surgical automation, miniaturisation, wireless integration) rather than fundamentally new neuroscience.
Beyond the company-specific debates, the broader BCI field has prompted ethical discussion about the privacy of neural data, the long-term safety of cortical implants, and the risk of inequitable access to a costly technology. Several review articles, including commentary on Neuralink's 2019 paper in JMIR and pieces in MIT Technology Review and IEEE Spectrum, have flagged the need for clearer governance of brain-recorded data once such systems leave the lab.
Neuralink has had an outsized effect on public attention to brain-computer interfaces, and on private capital flows into the field. The company's work on a coin-sized, wireless, high-channel-count implant inserted by a custom robot is a real engineering advance over older systems such as the Utah Array, particularly for ambulatory use outside a tethered lab setting. At the same time, the long-running [[brainco|BrainCo]] and BrainGate efforts and competitors such as Synchron, Blackrock Neurotech, Paradromics, and Precision Neuroscience continue to publish their own clinical milestones, and the cumulative human implant-years in the field still come mostly from older platforms. Whether Neuralink's particular bet (penetrating polymer threads with thousands of channels and an autonomous insertion robot) becomes the dominant clinical architecture, or sits alongside endovascular and surface-array approaches that trade resolution for invasiveness, is one of the central open questions for BCI in the second half of the 2020s.
The company is also notable as a counterpoint to Musk's other ventures in software-heavy artificial intelligence. Where firms such as [[google_brain|Google Brain]] (since merged into Google DeepMind) and other large research organisations have pursued AI capability primarily through scale on the algorithmic side, Neuralink represents a wager that bidirectional, brain-level interfaces will be a meaningful complement to or check on those systems over the long term.